NDA 208255 · Mylan
Symfi Lo
Efavirenz, Lamivudine, Tenofovir Disoproxil Fumarate · Oral
Priority reviewDiscontinuedLast checked: Nov 19, 2026Latest source record: Oct 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Feb 5, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
432
116 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SYMFI LO · EFAVIRENZ 400MG; LAMIVUDINE 300MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Efavirenz" as an intervention, any sponsor and status, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00118898 · 1,864 participants · Start Sep 2005 · Primary completion Nov 2009
Drug: Abacavir/Lamivudine; Atazanavir and 5 more · For: HIV Infections
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 52 sites in all
- Antiretroviral Therapy for Advanced HIV Disease in South AfricaPivotal-lookingCompleted
National Institutes of Health Clinical Center (CC)NIH
NCT00342355 · 1,771 participants · Start Jan 2004 · Primary completion Mar 2008
Drug: Zidovudine; Stavudine and 4 more · For: HIV
Sites: Centurion, South Africa; Eastaern Cape, South Africa; Free State, South Africa · 7 sites in all
- A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000922 · 1,710 participants · Primary completion Jan 2003
Drug: Indinavir sulfate; Abacavir sulfate and 6 more · For: HIV Infections
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 17 sites in all
- Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited SettingsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00084136 · 1,571 participants · Start May 2005 · Primary completion May 2010
Drug: Atazanavir; Didanosine (enteric-coated) and 4 more · For: HIV Infections
Sites: Los Angeles, California; Torrance, California; Denver, Colorado · 42 sites in all
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01815736 · 1,443 participants · Start Mar 27, 2013 · Primary completion Mar 16, 2015
Drug: E/C/F/TAF; E/C/F/TDF and 5 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 167 sites in all
- Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in AfricaPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT02028676 · 1,206 participants · Start Mar 2007 · Primary completion Mar 2012
Drug: Arm A: ABC+3TC+NNRTI; Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance and 4 more · For: Human Immunodeficiency Virus
Sites: Entebbe, Uganda; Kampala, Uganda; Mulago, Uganda · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Symfi Lo (Efavirenz/Lamivu/Tenofov Disop)
2024 spending
$63K
Beneficiaries
n/a
24 claims
Per beneficiary
n/a
$52.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $462,760 |
| 2021 | $236,943 |
| 2022 | $129,278 |
| 2023 | $134,569 |
| 2024 | $63,185 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Pettit AC, Phillips PPJ, Kurbatova E, et al. · Clin Infect Dis 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL, Antela A, Clumeck N, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Multicenter Study
- Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kryst J, Kawalec P, Pilc A · PLoS One 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Drug-drug interactions between antiretrovirals and hormonal contraception: An updated systematic review.
Todd CS, Lorenzetti L, Mussa A, et al. · Contraception 2024 · Systematic Review, Research Support, U.S. Gov't, Non-P.H.S.
- Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist.
Gehin M, Wierdak J, Sabattini G, et al. · Br J Clin Pharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Kajubi R, Huang L, Jagannathan P, et al. · Clin Pharmacol Ther 2017 · Randomized Controlled Trial
Sponsor: Mylan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.